Frequently Asked Questions About Moderna Inc (MRNA) Stock
Moderna Inc's (MRNA) last reported annual revenue was USD 6.85 Billion.
Moderna Inc's (MRNA) annual revenue growth rate based on the revenue reported in the past 5 years is : 123.60%
Moderna Inc's(MRNA) is not profitable as of its last reported annual financials.
The net profit margin for Moderna Inc's(MRNA) from its laster reported year is -68.84%
The return on equity (ROE) for Moderna Inc's(MRNA) from its last reported annual financials is : -17.52%
The return on assets (ROA) for Moderna Inc's(MRNA) from its last reported annual financials is : -9.55%
The return on invested capital (ROIC) for Moderna Inc's(MRNA) from its last reported annual financials is : -30.39%
The Debt to Equity ratio for Moderna Inc's(MRNA) from its last reported annual financials is : 0.00%
The dividend yield for Moderna Inc's(MRNA) from its laster reported year is 0.00%
Moderna Inc's(MRNA) has negative cash flow as of its last reported annual financials.
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for MRNA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
